doi.org/10.1016/s1470-2045(20)30445-9
Original paper

Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study

..., Wilson H. Miller
74
The Lancet Oncology41.60
Volume: 21, Issue: 10, Pages: 1353 - 1365
Published: Sep 10, 2020
Paper Fields
Paper Details
Title
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study
DOI
doi.org/10.1016/s1470-2045(20)30445-9
Published Date
Sep 10, 2020
Journal
The Lancet Oncology
Volume
21
Issue
10
Pages
1353 - 1365
© 2025 Pluto Labs All rights reserved.